Overview

Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis

Status:
Completed
Trial end date:
2014-08-15
Target enrollment:
Participant gender:
Summary
The primary objectives of this study were to determine the rate, extent, and routes of radioactivity excretion of [¹⁴C]etelcalcetide in feces, dialysate, and urine over time and to measure radioactivity concentrations in whole blood and plasma over time.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen